Metabolomic biomarkers as strong correlates of Parkinson disease progression

Neurology

Volumn 88, Issue 9, 2017, Pages 862-869

  Lewitt, Peter A ^a,c   Li, Jia ^b   Lu, Mei ^b   Guo, Lining ^d   Auinger, Peggy ^e  

^a Department of Neurology ^*  (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d METABOLON INC   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 NONADECENOATE; 2 ETHYLHEXANOIC ACID; 3 HYDROXYDECANOATE; 5 DODECENOATE; BENZOIC ACID; BIOLOGICAL MARKER; DOCOSADIENOATE; DOCOSATRIENOATE; DODECANEDIOATE; EICOSENOATE; HOMOVANILLIC ACID; INDOLEACETIC ACID; LONG CHAIN FATTY ACID; MANNITOL; METHYL BETA GLUCOPYRANOSIDE; MYRISTOLEATE; N 6 TRIMETHYLLYSINE; OXALIC ACID; PALMITOLEIC ACID; PEPTIDE DERIVATIVE; SERINE; TARTARIC ACID; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID; XANTHINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; METABOLOMICS; PARKINSON DISEASE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE; BLOOD; CEREBROSPINAL FLUID; CLINICAL TRIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLOME; MIDDLE AGED; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AGED; BIOMARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LINEAR MODELS; MALE; METABOLOME; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 85014104529     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003663     Document Type: Article

References (36)

1. Andersen AD, Binzer M, Stenager E, Gramsbergen JB. Cerebrospinal fluid biomarkers for Parkinson's disease: a systematic review. Acta Neurol Scand 2017; 135: 34-56.
2. Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015; 84: 57-63.
3. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014; 29: 1010-1018.
4. Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee in Parkinson's disease. Mov Disord 2014; 29: 976-979.
5. Carvalho C, Correia SC, Cardoso S, et al. The role of mitochondrial disturbances in Alzheimer, Parkinson and Huntington diseases. Expert Rev Neurother 2015; 15: 867-884.
6. Vilchez D, Saez I, Dillin A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun 2014; 5: 5659.
7. Caudle WM, Bammler TK, Lin Y, Pan S, Zhang J. Using "omics" to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev Neurother 2010; 10: 925-942.
8. Evans AM, DeHaven CD, Barrett T, MitchellM, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81: 6656-6667.
9. Lawton KA, Berger A, Mitchell M, et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 2008; 9: 383-397.
10. Guo L, Milburn MV, Ryals JA, et al. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Soc USA 2015; 112: E4901-E4910.
11. Hiller K, Hangebrauk J, Jäger C, Spura J, Schreiber K, Schomburg D. MetaboliteDetector: comprehensive analysis tool for targeted and nontargeted GC/MS based metabolome analysis. Anal Chem 2009; 81: 3429-3439.
12. LeWitt P, Galloway M, Matson W, et al. Markers of dopamine metabolism in Parkinson's disease. Neurology 1992; 42: 2111-2117.
13. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-1371.
14. Fahn S, Elton RL. UPDRS Program Members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent Developments in Parkinson's Disease, Vol. 2. Florham Park: Macmillan Healthcare Information; 1987: 153-163.
15. Parkinson Study Group. CSF homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995; 52: 237-245.
16. LeWitt PA, Li J, LuM, BeachTG, AdlerCH, Guo L; Arizona Parkinson's Disease Consortium. 5-Hydroxykynurenine and other biomarkers of Parkinson's disease discovered by metabolomic analysis. Mov Disord 2013; 28: 1653-1660.
17. Dehaven CD, Evans AM, Dai H, Lawton KA. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform 2010; 2: 9.
18. Nyamundanda G, Gormley IC, Fan Y, Gallagher WM, Brennan L. MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinformatics 2013; 14: 338.
19. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445.
20. Tibshirani R. Regression shrinkage and selection via the lasso. J R Statist Soc B 1996; 58: 267-288.
21. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69: 570-580.
22. Michell AW, Mosedale D, Grainger DJ, Barker RA. Metabolomic analysis of urine and serum in Parkinson's disease. Metabolomics 2008; 4: 191-201.
23. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008; 131: 389-396.
24. Johansen KK, Wang L, Aasly JO, et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009; 4: e7551.
25. Roede JR, Uppal K, Park Y, et al. Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study. PLoS One 2013; 8: e77629.
26. Luan H, Liu LF, Meng N, et al. LS-MC-based urinary metabolite signatures in idiopathic Parkinson's disease. J Proteome Res 2015; 14: 467-468.
27. Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry 2016; 87: 295-301.
28. LeWitt PA, Huber BR, Zhang J. An update on CSF biomarkers of Parkinson's disease. In: Mandel S, editor. Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future: Advances in Predictive, Preventive, and Personalized Medicine, Vol. 2. Dordrecht: Springer; 2013: 161-184.
29. Garcia-Esparcia P, Hernández-Ortega K, Ansoleaga B, Carmona M, Ferrer I. Purine metabolism gene deregulation in Parkinson's disease. Neuropathol Appl Neurobiol 2015; 41: 926-940.
30. Palacios N, Gao X, McCullough ML, et al. Caffeine and the risk of Parkinson's disease in a large cohort of men and women. Mov Disord 2013; 27: 1276-1282.
31. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66: 1460-1468.
32. Loeffler DA, LeWitt PA, Juneau PL, et al. Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover. Brain Res Bull 1998; 45: 297-299.
33. Tyurina YY, Polimova AM, Maciel E, et al. LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenonetreated rats: implication for mitochondrial dysfunction in Parkinson's disease. Free Radic Res 2015; 49: 681-691.
34. Farmer K, Smith CA, Hayley S, Smith J. Major alterations of phosphatidylcholine and lysophosphotidyl lipids in the substantia nigra using an early stage model of Parkinson's disease. Int J Mol Sci 2015; 16: 18865-18877.
35. Katsuki H, Nonaka M, Shirakawa H, Kume T, Akaike A. Endogenous D-serine is involved in induction of neuronal death by N-methyl-D-aspartate and simulated ischemia in rat cerebrocortical slices. J Pharmacol Exp Ther 2004; 311: 836-844.
36. Meiser J, Delcambre S, Wegner A, et al. Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism. Neurobiol Dis 2016; 89: 112-125.